| Code | 1750E | ||||||||||
| MA number | 44/0075/22-S | ||||||||||
| Product Form: | cps dur 28x12,5 mg (fľ.HDPE) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | MSN LABS EUROPE Limited, Malta | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 09.09.2022 |
| Validity: | 09.09.2027 |
| PIL: |
PIL_Sunitinib MSN 12,5 mg, 25 mg, 37,5 mg, 50 mg cps dur_08_2022.pdf
|
| SPC: |
SPC_Sunitinib MSN 12,5 mg, 25 mg, 37,5 mg, 50 mg cps dur_ 08_2022.pdf
|
| Safety feature | Yes |
| Data update: | 21.09.2022 |
